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PIK3CA mutations are common in lobular
carcinoma in situ, but are not a biomarker
of progression
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Anita Grigoriadis2, Trevor A. Graham3, Rebecca Roylance4, Michael A. Simpson5, Sarah E. Pinder1
and Elinor J. Sawyer1*
Abstract
Background: Lobular carcinoma in situ (LCIS) is a non-invasive breast lesion that is typically found incidentally on
biopsy and is often associated with invasive lobular carcinoma (ILC). LCIS is considered by some to be a risk factor
for future breast cancer rather than a true precursor lesion. The aim of this study was to identify genetic changes
that could be used as biomarkers of progression of LCIS to invasive disease using cases of pure LCIS and
comparing their genetic profiles to LCIS which presented contemporaneously with associated ILC, on the
hypothesis that the latter represents LCIS that has already progressed.
Methods: Somatic copy number aberrations (SCNAs) were assessed by SNP array in three subgroups: pure LCIS,
LCIS associated with ILC and the paired ILC. In addition exome sequencing was performed on seven fresh frozen
samples of LCIS associated with ILC, to identify recurrent somatic mutations.
Results: The copy number profiles of pure LCIS and LCIS associated with ILC were almost identical. However, four
SCNAs were more frequent in ILC than LCIS associated with ILC, including gain/amplification of CCND1. CCND1 protein
over-expression assessed by immunohistochemical analysis in a second set of samples from 32 patients with pure LCIS
and long-term follow up, was associated with invasive recurrence (P = 0.02, Fisher’s exact test). Exome sequencing
revealed that PIK3CA mutations were as frequent as CDH1 mutations in LCIS, but were not a useful biomarker of LCIS
progression as they were as frequent in pure LCIS as in LCIS associated with ILC. We also observed heterogeneity of
PIK3CA mutations and evidence of sub-clonal populations in LCIS irrespective of whether they were associated with ILC.
Conclusions: Our data shows that pure LCIS and LCIS co-existing with ILC have very similar SCNA profiles, supporting
the hypothesis that LCIS is a true precursor lesion. We have provided evidence that over-expression of CCND1 may
identify a subgroup of patients with pure LCIS who are more likely to develop invasive disease, in contrast to PIK3CA
mutations, which occur too early in lobular tumorigenesis to be informative.
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Background
Lobular carcinoma in situ (LCIS) is a non-invasive breast
lesion that is typically found incidentally on biopsy but is
also often seen in the presence of invasive lobular carcin-
oma (ILC), which accounts for 10–15% of all invasive
breast carcinomas. Hwang et al. showed that ILC and co-
existing LCIS share many of the same genetic aberrations
[1]. Furthermore, Vos et al. demonstrated the presence of
the same truncating mutations in CDH1 and loss of
heterozygosity (LOH) of the wild-type E-cadherin in the
LCIS component and adjacent ILC [2].
These studies suggest that LCIS is a non-obligate pre-
cursor of ILC in a manner analogous to ductal carcinoma
in situ (DCIS) preceding invasive ductal carcinoma of no
special type (IDC). However, the risk of invasive cancer
after LCIS is lower than that with DCIS (2–11 times
greater than the risk in the general population, in contrast
to DCIS with 20 times greater risk) [3, 4], and the overall
rate of progression of pure LCIS to ipsilateral ILC has
been shown to be <10% ten years after the diagnosis of
LCIS [5, 6]. LCIS is also considered a risk factor for future
breast cancer, as not all invasive disease post LCIS pre-
sents as ILC and, unlike DCIS, LCIS is also a risk factor
for developing invasive cancer in the contralateral breast
[7]. Fisher et al. reported that 80% of invasive disease post
LCIS is ILC; however, it is likely that the patients in that
study did not represent typical cases of classical LCIS
(cLCIS) as many were initially diagnosed as having DCIS,
but on pathological review were determined to have LCIS
[8]. A more recent study has reported much lower rates of
ILC post LCIS (27%), although this was still higher than
the expected 10–15% [6].
The timescale for the development of invasive carcin-
oma after an initial diagnosis of LCIS in either breast var-
ies greatly between individuals; one study demonstrated
that two thirds of patients developed invasive disease
within 15 years; however, another study found that 50% of
patients developed ILC up to 15 to 30 years later. This has
led some to argue against LCIS as a non-obligate precur-
sor lesion and to suggest that “pure” LCIS may have a
different molecular profile compared to LCIS that co-
exists with invasive disease, and that the molecular studies
cited above have focused on LCIS with associated ILC,
rather than pure LCIS.
There are limited studies of pure LCIS but generally these
do show similar genetic changes to LCIS associated with
ILC, with 16q loss and 1q gain being the most common
chromosomal abnormalities. Whilst Mastracci et al. sug-
gested that LOH at 16q was infrequent in 13 cases of pure
LCIS [9], comparative genomic hybridization studies on 17
cases of pure LCIS revealed 16q loss in 88% of cases, being
the sole detected alteration in 29% [10]. In the latter study,
1q gain was the second most common change, occurring in
41% of tumours and in all cases associated with 16q loss.
There is also evidence of E-cadherin loss in both LCIS and
atypical hyperplasia with CDH1 mutations being common
in LCIS, but rare in atypical lobular hyperplasia (ALH) [11].
The increased breast biopsy rate associated with screen-
ing mammography has led to an increase in the diagnosis
of pure LCIS in postmenopausal women [12] with around
3% of needle biopsies identifying pure LCIS [13]. Current
guidelines for patients with a diagnosis of LCIS highlight
the need for increased surveillance of both the affected
and contralateral breasts; however, the optimum manage-
ment of women with pure LCIS is unclear, as not all
women with LCIS will develop invasive disease. Currently
in the UK patients with pure LCIS do not receive any
further treatment and, even if incompletely excised, no
further surgery is performed. There is now convincing evi-
dence from large randomized chemoprevention trials, that
5 years of endocrine therapy reduces the risk of invasive
disease after a diagnosis of LCIS by 50%; the NASBP-P1
study demonstrated that 5 years of tamoxifen reduced the
development of invasive disease after LCIS from 11% in
the control group to 4% in the tamoxifen-treated group
[14]. Similarly 5 years of exemestane reduced invasive dis-
ease from 13 to 6%, respectively [15]. However, despite
this evidence, the use of chemoprevention for LCIS has
not become common practice; seemingly clinicians and
patients feel that as many cases of LCIS do not progress
to invasive disease, the benefits of chemoprevention do
not outweigh the potential side effects. It would therefore
be invaluable to have biomarkers to predict the likelihood
of progression of LCIS, so that appropriate screening and
treatment can be offered.
Current biomarker data in LCIS are very limited [16].
There is some evidence to suggest the risk of subsequent
invasive disease is associated with high Ki67 expression [17]
and that increased expression of hsa-miR-375 contributes
to lobular neoplastic progression [18]. Other studies have
shown that the five biomarkers known to be important in
invasive breast cancer (oestrogen receptor (ER), progester-
one receptor (PgR), c-erbB-2, p53 and Ki-67 expression) do
not predict progression of LCIS [19]. One of the problems
with studies that have tried to identify biomarkers that pre-
dict LCIS recurrence is the small number of cases analysed
due to the rarity of pure LCIS.
The aim of the present study was to identify genetic
changes that could be used as biomarkers of progression
of LCIS to invasive disease. Ideally this should be done in
a cohort of patients with pure LCIS, who have progressed
to invasive disease, compared to a cohort that have not,
but such patients are very rare. We therefore chose to do
our discovery phase using patients with pure LCIS and
comparing their genetic profiles to patients with LCIS
who presented contemporaneously with associated ILC,
based on the hypothesis that the latter represents LCIS
that has already progressed.
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Methods
Samples
Archival cases were identified from the study to investi-
gate the genetics of lobular carcinoma in situ in Europe
(GLACIER) (06/Q1702/64). In this study blood samples
and formalin-fixed paraffin-embedded (FFPE) tumour
samples were available for women with LCIS from 97 hos-
pitals throughout the UK, together with data on known
hormonal risk factors for breast cancer. For the discovery
phase 30 patients with classic pure LCIS (pure-cLCIS) and
30 with classic LCIS associated with ILC (inv-cLCIS) were
selected for SNP-array analysis to assess copy number
changes, together with 7 patients with classic LCIS with
ILC who had fresh-frozen lesions stored in the KHP
Cancer Biobank (NHS REC ref. 12-EE-0493), which were
used for whole exome sequencing in order to assess the
frequency of mutations in inv-cLCIS.
Following independent review by a breast histopatholo-
gist (SEP) to confirm the diagnosis, samples were visually
assessed to determine the presence of sufficient malignant
tissue for needle dissection under a light microscope
(macrodissection). E-cadherin expression was also assessed
by immunohistochemical analysis and in all cases E-
cadherin staining was absent within the LCIS/ILC with the
exception of one pure LCIS sample, which had occasional
foci of patchy weak membrane staining.
Up to 20 10-μm sections were stained using Nuclear Fast
Red (Sigma) and macrodissected to separate the LCIS and
invasive components. In order to obtain enough DNA to
perform these experiments, all the pure-cLCIS foci in a sin-
gle FFPE block were macrodissected (maximum area 2 cm2).
In samples from 23 women with inv-cLCIS, this was on the
same block as the invasive tumour and in samples from 5
women it was on an adjacent block. Tumour DNA was ex-
tracted using the QIAamp DNA FFPE Tissue Kit (Qiagen)
for archival specimens and the DNeasy Blood & Tissue Kit
(Qiagen) for fresh-frozen samples. Patient-matched germline
DNA was extracted from peripheral blood samples using
the Nucleon product chemistry (Tepnel, Manchester, UK).
DNA was quantified using Quant-iT™ PicoGreen® dsDNA
Assay Kit (Life Technologies).
For the validation of potential biomarkers, we studied
samples from 37 patients with pure LCIS, who were
diagnosed between 1980 and 2011 and had been followed
up for longer than 6 months (median follow up was 81
months, range 34–333). A table summarizing all the
clinico-pathological data on the samples used in this study
can be found in Additional file 1: Table S1 (discovery set)
and Additional file 1: Table S2 (validation set).
SNP arrays
Samples were hybridised onto the Oncoscan™ Affymetrix
array. The array uses molecular inversion probe (MIP)
technology to detect 335,000 markers for genome-wide,
allele-specific copy numbers with enhanced coverage of
known cancer genes, and which also provides a mutation
score for the likelihood of the sample containing a somatic
mutation in a series of key cancer genes (http://www.affy-
metrix.com). A minimum of 200 ng DNA for each sample
was used. Labelling and hybridization were outsourced to
Affymetrix (Santa Clara, CA, USA).
Raw array data was preprocessed with Nexus 7.5 software
(BioDiscovery), applying the SNPRank segmentation algo-
rithm with a minimum of 10 probes per segment. Tumour
Aberration Prediction Suite (TAPS) 2.0 [20] was used to de-
termine absolute copy number and for categorisation into:
gains (copy number (CN) =/> 3); amplification (CN>/=5),
losses (CN =/< 1); and copy neutral LOH (cnLoH). Samples
found to have whole genome duplication were corrected to
a diploid state. Frequency plots were made using the copy
number package in R 3.0.0 (https://www.bioconductor.org/
packages/release/bioc/html/copynumber.html).
Frequency tables of the resulting somatic copy number
aberrations (SCNAs) were generated for pure LCIS, the
LCIS associated with ILC, and the paired ILC, and the
prevalence of SCNAs were compared using Fisher’s exact
test. Genomic regions with statistically significant differences
(P < 0.05) but reported in regions of known HAPMAP copy
number variations (CNVs) (http://hapmap.ncbi.nlm.
nih.gov/) were removed.
Two-way hierarchical clustering of the pure LCIS, inv-
LCIS, and ILC samples was performed using Manhattan
distance and Ward’s clustering method in the NMF package
in R (http://nmf.r-forge.r-project.org/aheatmap.html) based
on type SCNA (=/>100 probes) occurring on each p and q
arm. The raw data are available (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE88909).
Immunohistochemical analysis (IHC) and fluorescence in
situ hybridization (FISH)
CCND1 FISH was performed using 4-μm tissue sections
treated with SPOT-Light® Tissue Pretreatment kit (Life
Technologies) prior to hybridisation with Abbott Molecular
Vysis LSI CCND1 and chromosome 11 enumeration probe
kit (Abbott Molecular Inc.) according to the manufacturer’s
instructions. The 11q13 probe covers a genomic region of
378 kb and includes the following genes: CCND1, FGF19
and FGF4. CCND1 and chromosome 11 enumeration
probe (CEP11) foci were counted in a minimum of 20 cells
and an average was determined. The ratio of CCND1 to
CEP11 foci was calculated and gain was defined as a ratio
of 1.5–2.5 and amplification >2.5.
CCND1 IHC was performed on 3-μM FFPE tissue sec-
tions using clone SP4-R (Ventana Medical Systems Inc.) on
an automated staining system (VENTANA BenchMark
ULTRA, Roche). CCND1 was scored as described previ-
ously by Reis-Filho et al. [21] (equivalent to the Allred scor-
ing system for ER) and based on the proportion of stained
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nuclei (scored 0–5: 0 = none; 1 = <1/100; 2 = 1/100–1/10; 3
= 1/10–1/3; 4 = 1/3–2/3 and 5 = >2/3) and intensity (0–3:
0 = no staining; 1 = weak staining visible only at high
magnification; 2 =moderate staining and 3 = strong staining
visible at low magnification). The two scores were com-
bined to give a total score (0–8: 0–2 = low; 3–5 = inter-
mediate and 6–8 = high).
Whole exome sequencing (WES)
Libraries were prepared from tumour and paired germline
DNA using the SureSelect Human All Exon 50 Mb kit
(Agilent) and sequenced on Illumina HiSeq 2000 to a mean
depth > ×100. Subsequent analysis was performed using our
in-house pipeline; in brief, sequencing reads were aligned to
the reference human genome hg19 using NovoAlign (http://
www.novocraft.com/products/novoalign/), Samtools [22] was
used to create a pileup file and VarScan2 [23] was used
to call somatic mutation and indels, annotated using
ANNOVAR [24] and cross-referenced with dbSNP and
1000 Genomes. Somatic mutations were called if there
was a minimum of × 30 coverage and the mutation was
present in at least 10% of reads.
Sanger sequencing
Using standard protocols on the Applied Biosystems 3730xl
DNA analyzer with the Finch TV software (Geospiza),
Sanger sequencing confirmed the presence of mutations
detected by the Oncoscan array or exome sequencing. A
restriction enzyme enrichment protocol on stock DNA was
used [25] for mutations in exon 9 of PIK3CA (c1624G_A
and c1633G_A).
Assessing tumour heterogeneity using the SNP-array
For regions with a copy number score between 1 and 2 on
TAPs analysis, i.e. not being designated as loss by the
algorthim but showing some loss visually, we used highly
polymorphic microsatellite markers to assess whether these
segments represented areas of sub-clonal loss or were just
experimental variation in calling of copy number 2, by
extracting DNA from different areas of LCIS microdissected
using the PALMMicroBeam laser capture microscope (Carl
Zeiss). Microsatellite markers on 16q (D16S752) or 6q
(D6S1627) were used as a “control”, as these regions were
designated as loss (copy number 1) by TAPs.
Having confirmed that the segments that did not reach
the threshold for loss did represent subclonal events, we
plotted the transformed log2 ratio and transformed b-allele
frequency (allelic imbalance score from TAPS 2.0 output)
for each segment of loss to count the number of these seg-
ments that were subclonal per sample. Samples in which
the three clusters (absolute copy numbers 1, 2 and 3) could
not be defined due to poor quality of the DNA or poor hy-
bridisation were excluded (three cILC, three inv-cLCIS and
5 pure cLCIS samples). The segment with an absolute copy
number of 1 with the lowest log2 ratio and highest allelic
imbalance score in a sample was assumed to be a clonal
event and to be present in 100% of the tumour cells (gener-
ally 16q), and it was used as the reference for copy number
1. The Euclidian distance was calculated from the centroid
of all the diploid segments to this reference segment. Next
the distance of the remaining segments from the diploid
centroid was calculated as a proportion of this reference
distance (Additional file 2: Figure S1). A sample-specific
threshold was established by examining the distribution of
the proportions of the segments considered to be diploid
by TAPS output. The threshold for sub-clonality was de-
fined as being outside the 99th percentile of this distribu-
tion. Applying this threshold to all the segments
considered to be copy number 1 in the TAPS output iden-
tified sub-clonal segments.
Results
SNP array-based copy number analysis of classical LCIS
In the discovery set, adequate DNA for hybridization onto
the Oncoscan V2 array was extracted from 27/30 samples
of pure classic LCIS, and from the 30 samples of classic
LCIS associated with ILC, 28 had adequate DNA ex-
tracted from the LCIS component and 25 from the ILC
component. Frequency plots of gains and losses within
each group revealed similar patterns, Fig. 1a.
Pure-cLCIS and inv-cLCIS had remarkably similar
SCNAs. There was no evidence that pure-cLCIS was any
less genetically re-arranged than inv-cLCIS, with pure LCIS
samples not clustering together but scattered throughout
the inv-LCIS and ILC samples on hierarchical clustering
(Fig. 1b). In fact aneuploidy was more common in the
pure-cLCIS group with three cases being triploid, and one
case having complex genetic re-arrangements suggestive of
chromothripsis; none of the inv-cLCIS cases had evidence
of such changes (Additional file 2: Figure S2).
All cLCIS samples, irrespective of whether or not they
were associated with ILC, had loss or cnLOH of 16q as did
24/25 of the paired cILC. One ILC sample had visual evi-
dence of low-level 16q loss but did not reach the threshold
for copy number 1 using the TAPS algorithm, most likely
due to normal tissue contamination, as there was no evi-
dence of E-cadherin expression on IHC. As expected, gain
or cnLOH of 1q was the second most frequent change oc-
curring in 21/27 pure c-LCIS samples (78%), 25/28 inv-
cLCIS samples (89%) and 21/25 cILC samples (84%). These
two genetic changes clustered strongly together (Fig. 1b),
and were the sole SCNAs in five pure - cLCIS and 3 inv-
cLCIS samples. Other frequent SCNAs that occurred in all
subtypes were gain of 16p (8/27 pure-cLCIS, 5/28 inv-
cLCIS and 9/25 cILC samples) and gain of 19p (9/27 pure-
cLCIS, 6/28 inv-cLCIS and 2/25 cILC samples) and loss of
17p (7/27 pure-cLCIS, 8/28 inv-cLCIS and 12/25 cILC
samples). Smaller regions (<10 Mb) of gain were found on
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Fig. 1 a Summary of copy number changes in pure classic lobular carcinoma in situ (pure-cLCIS), classic lobular carcinoma in situ associated with invasive
lobular cancer (inv-cLCIS) and classic lobular invasive cancer (cILC). b Two-way hierarchical clustering of the pure-cLCIS, inv-cLCIS and cILC based on type
of somatic copy number aberration (SCNA) (=/>100 probes) occurring on each p and q arm. (cnLOH = copy neutral loss of heterozygosity)
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1p34.1, 3p14.1, 9q33.3 and 17q11.2, and of loss were found
on 17p13.1 and these occurred with similar frequency in
both pure-cLCIS and inv-cLCIS (Additional file 1: Table
S3). Of these, only 3p14.1 gain, containing the transcription
factor MITF, and loss on 17p13.1 loss (TP53), were found
with similar or increased frequency in the paired ILC.
Amplifications (defined as copy number =/> 5) were
found in 15 pure-cLCIS samples and 14 inv-cLCIS samples
(Additional file 1: Table S4). The most common amplifica-
tions in cLCIS were on 1q, encompassing AKT3 (4/27
pure-cLCIS, 4/28 inv-cLCIS and 4/25 ILC samples) and
11q13, encompassing CCND1 (0/27 pure-cLCIS, 2/28 inv-
cLCIS and 5/25 cILC samples).
The only SCNAs that were significantly different be-
tween pure-cLCIS and inv-cLCIS were five small regions
of gain, more common in pure LCIS, three of which
contained a single gene: Xp11 (KLF8), 20p12.1
(MACROD2) and 17q11.2 (RAB11FIP4) (Table 1).
Only one inv-cLCIS/cILC pair clustered together
(Fig. 1b); however, this was because in the majority of
inv-cLCIS samples the invasive component had the same
SCNAs as its paired LCIS but had also acquired add-
itional genetic changes, with SCNAs being more com-
mon in cILC than in inv-cLCIS (P = 0.003) (Additional
file 2: Figure S3). Four regions had an increase in fre-
quency from pure-cLCIS through to inv-cLCIS and
cILC: loss of 6q, 8p23 and 22q13 and gain/amplification
of 11q13 (Table 1). Among the three regions of loss the
most significant increase in frequency came in the tran-
sition from inv-cLCIS to cILC.
Gain/amplification of 11q13, was considered potentially
the most useful biomarker of LCIS progression, as none of
the pure LCIS samples had gain/amplification, but four
(two gain, two amplification) of the inv-cLCIS did, with
amplification becoming more common in the invasive
component. Analysis of the amplicons in our samples re-
vealed that the minimal region of gain/amplification was
Chr11: 68961001–70183017, Fig. 2a. This region includes
a number of potential oncogenes including CCND1,
FGF19, FGF4 and FGF3. FISH using a probe encompass-
ing CCND1, FGF19 and FGF4 confirmed the presence of
gain/amplification of 11q13 in all samples with gain/amp-
lification on the SNP array, Fig. 2b. IHC was performed
on all samples in the discovery set and this showed that all
samples with gain/amplification of 11q13 also had high
expression (score ≥6) of cyclin D1. IHC also detected
other samples with high protein expression but no evi-
dence of amplification. There was a trend towards higher
Table 1 Summary of somatic copy number aberrations showing a difference in frequency between pure-cLCIS, inv-cLCIS and cILC
Chr Region Genes Type of
SCNA
PURE
c-LCIS (27)
INV-
cLCIS (28)
cILC
(25)
P_values
Pure cLCIS vs
INV-cLCIS
INV-cLCIS vs
cILC
Across all 3
groups
5 39436375-39620648
(p13.1)
LOC101926940 Gain 4 0 3 0.05 0.1 0.1
5 129741359-131422972
(q23.3 – q31.1)
HINT1, LYRM7, CDC42SE2,
RAPGEF6, FNIP1,MEIKIN,
ACSL6, IL3, CSF2
Gain 4 0 2 0.05 0.2 0.09
6 82391438-171115067
(q14.1 – q27)
Many including: MAP3K7, FOXO3,
ESR1, IGF2R, MAP3K4, etc.
Loss 0 2 10 0.5 0.007 0.00007
8 5412833-8927086
(p23.2-p23.1)
MCPH1, ANGPT2, AGPAT5, XKR5,
Defensins, FAM66B,SPAG11B &A,
CLDN23, ERI1
Loss 1 2 9 1 0.04 0.002
10 75541103-76515425
(q22.2)
CHCHD1,VCL,PLAU,ADK,AP3M1,
CAMK2G, NDST2
Gain 2 0 5 0.2 0.05 0.03
11 68961001-71551048
(q13.3 – q13.4)
CCND1, MYEOV, FGF4, FGF3 Gain
(Amp)
0 4 (2) 6 (5) 0.1 0.1 0.02
17 29779560-29899917
(q11.2)
RAB11FIP4 Gain
(Amp)
5 (1) 0 0 0.02 0.005 0.005
18 727180-742194
(p11.32)
YES1 Gain
(Amp)
7 (1) 2 0 0.07 0.02 0.02
X 55670623-57693679
(p11.21)
KLF8 Gain 10 0 1 0.0003 0.00004 0.00004
20 14695735-15225214
(p12.1)
MACROD2 Gain 6 0 1 0.01 0.006 0.006
22 47751337-51304566
(q13.31 - q13.3)
BRD1, HDAC10, MAPK12.
MAPK11 ….
Loss 2 4 13 0.6 0.005 0.0003
Pure-cLCIS pure classic lobular carcinoma in situ, inv-cLCIS classic lobular carcinoma in situ associated with invasive lobular cancer, cILC classic invasive lobular
cancer, Chr chromosome, SCNA somatic copy number aberration
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cyclin D1 expression from pure LCIS through to inv-
cLCIS and ILC (P = 0.07) (Fig. 2c).
In order to assess whether expression of cyclin D1 could
be a potential marker of progression, IHC was performed
on a different set of samples from 32 patients from the
GLACIER study, who had long term follow up and FFPE
blocks available, and had not received chemoprevention or
had undergone mastectomy (Additional file 1: Table S2). Of
these 32 patients, 8 had developed invasive disease with a
median time to recurrence of 69 months (range 34–175).
Four had developed ipsilateral recurrence (two ILC, one
IDC, one ILC and IDC) and four, contralateral invasive
disease (one tubular carcinoma, one IDC and two ILC)
(Additional file 1: Table S2a). The latter were excluded from
the analysis as they do not represent direct clonal progres-
sion of LCIS. Cyclin D1 protein overexpression was
associated with recurrence (P= 0.02, Fisher’s exact test) with
high expression in 4/4 samples from patients with pure
LCIS that progressed to ipsilateral invasive disease, com-
pared to only 8/24 samples from patients with pure LCIS,
a
b
c
Fig. 2 a Minimal region of gain/amplification on 11q; b correlation of copy number change at 11q13 with fluorescence in situ hybridization (FISH) using
the probe for CCND1 and Cyclin D1 immunohistochemical analysis (IHC); c frequency of Cyclin D1 expression as measured by IHC in the discovery set.
(SNP = single nucleotide polymorphism, LCIS = lobular carcinoma in situ, Inv LCIS = lobular carcinoma in situ associated with invasive lobular cancer)
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with no evidence of recurrence after a minimum of 60
month follow up.
IHC had a positive predictive value (PPV) of 33% and
negative predictive value (NPV) of 100%. FISH was only
performed on samples in the validation set with high cyclin
D1 expression on IHC, as our data and others [26] have
shown correlation between amplification and high expres-
sion on IHC. One of the four patients that developed
ipsilateral invasive disease (Fig. 2c-iv) had amplification of
CCND1 and subsequently developed ILC, which was treated
with mastectomy and endocrine therapy but recurred 2
years later in the mastectomy scar. The invasive recurrence
also had CCND1 amplification. One of the 24 patients
with long-term follow up and no evidence of recurrence
had evidence of CCND1 gain (P = 0.27, Fisher’s exact test).
Mutation analysis
Seven fresh-frozen samples of classic ILC with associated
LCIS were selected for whole exome sequencing (WES)
and the two components were macrodissected under the
light microscope. Adequate DNA for WES of both the
ILC and LCIS components was obtained from only one
patient. In the remaining samples three had adequate
DNA from the LCIS component and three from the ILC.
In the single paired LCIS-ILC sample, 13 mutations
were shared between the two components, including two
PIK3CA mutations and one truncating CDH1 mutation, a
frameshift mutation in COX15 and stop-gain in DOCK2
(Additional file 1: Table S5a). There was no evidence that
these mutated genes targeted a particular biological path-
way (http://geneontology.org/). The ILC component had
23 mutations not found in the LCIS component, of which
5 were transcription factors (RB1, ARID4A, VGLL3,
ZNF341 and SIX1) (Additional file 1: Table S5b). Similarly
the LCIS component had mutations in 10 genes, not
found in the ILC component, suggesting there are also
driver and passenger mutations at the pre-invasive stage
(Additional file 1: Table S5c).
Analysis of the pooled exome sequencing data from all
samples revealed that CDH1 and PIK3CA were the most
common somatic mutations, which co-existed in 3/4
LCIS and 3/4 ILC samples (Table 2). The finding that
PIK3CA mutations were as common as CDH1 mutations
in LCIS was surprising and we therefore sequenced the
commonest mutations in exon 9 and 20 of PIK3CA
(c3140A > G, c3140A > T, c1624G > A, c1633G > A, c125
8T > C, c1636C > A) in the same samples that underwent
Oncoscan array analysis (27 pure-cLCIS and 28 inv-cLCIS
samples) to assess their frequency and determine whether
PIK3CA mutations could be used as a biomarker for LCIS
progression. Due to the limited amount of DNA, the
Oncoscan MIP array PIK3CA mutation score was used as
a guide as to which mutations to assess in each sample.
All PIK3CA mutations with an Oncoscan score >4.5 were
sequenced using Sanger sequencing. Sanger sequencing
DNA extracted from macrodissected samples did not
detect any mutations; however, the use of restriction
enzymes or microdissection of small areas of tissue using
the laser capture microscope (LCM) to minimise normal
tissue contamination, confirmed those mutations (Fig. 3).
In classic cases, 5/27 pure-cLCIS samples (18.5%) and 6/
28 inv-cLCIS samples (21.5%) had PIK3CA mutations. In
the latter group all of the mutations present in the LCIS
were also present in the paired ILC, with the exception of
two samples. One contained three different PIK3CA muta-
tions in the LCIS component and only two were transferred
to the paired ILC, and the other did not have enough DNA
to test the ILC component (Table 3).
These findings suggest that like CDH1, PIK3CAmutations
might be early events in lobular tumourigenesis, but are not
a potential biomarker for progression from LCIS to ILC.
Assessing tumour heterogeneity using Oncoscan MIP
array data
Exome sequencing revealed that mutations occurred in
10–24% of the reads in the LCIS samples and in 10–40%
of the ILC samples. As these samples were macrodissected
it is highly likely that there was significant normal tissue
contamination, particularly in the ILC samples due to the
Table 2 Whole exome sequencing of four invasive lobular cancer
(ILC) samples and four lobular carcinoma in situ (LCIS) samples
(one paired): mutations occurring in two or more samples
Gene Chrom Number of ILC
samples with
mutation
Number of LCIS
samples with
mutation
Total
HSPG2 1 1 1 2
ROR1 1 1 1 2
SMG7 1 1 1 2
TSSC1 2 2 0 2
PIK3CA 3 3 3 6
DOCK2 5 1 1 2
HAND1 5 2 0 2
UTP23 8 2 0 2
CACNB2 10 1 1 2
COX15 10 1 1 2
OR56B1 11 1 1 2
DDX11 12 1 1 2
PROSER1 13 1 1 2
TPTE2 13 1 1 2
PAK6 15 2 0 2
CDH1 16 3 3 6
PTRF 17 1 1 2
ATP11C X 1 1 2
ATRX X 1 1 2
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characteristic single cell file infiltration of breast stroma
seen in this subtype of carcinomas. However it is unlikely
that there was 80% normal tissue contamination in the
LCIS samples and we therefore tested the hypothesis that
heterogeneity within the LCIS could also be contributing
to the low number of reads with mutations. We sequenced
mutations from multiple areas within selected samples mi-
crodissected by LCM (two to six areas). In two pure-cLCIS
samples there was evidence of heterogeneity of the PIK3CA
mutation, Fig. 3a. In a sample with an ERBB2 mutation
there was evidence of heterogeneity within the in situ
component but not in ILC (Fig. 3b), and in one inv-cLCIS
Fig. 3 a Heterogeneity of PIK3CA mutations in two pure classic lobular carcinoma in situ (pure-cLCIS) samples; b heterogeneity of ERBB2 mutation within
the LCIS component but not in invasive lobular carcinoma (ILC); c heterozygous and homozygous PIK3CA mutations in invasive cLCIS associated with
ILC (inv-cLCIS)
Table 3 Frequency of PIK3CA mutations in classic lobular carcinoma in situ (LCIS)/invasive lobular cancer (ILC)
Mutation (total number of cases) Pure LCIS (27) inv-LCIS (28) ILC (25)
PIK3CA_pH1047R_c3140A_G 3 (1558,1717, 04078a) 3 (1731, 1965, 1604) 2a (1731,1604)
1965- no tissue left
PIK3CA_pH1047R_c3140A_T 0 0 0
PIK3CA_pE542K_c1624G_A 1 (1339) 3 (1063,1604, 1640) 3 (1063, 1604, 1640)
PIK3CA_pE545K_c1636C_A 0 0 0
PIK3CA_pE545K_c1633G_A 1 (1078) 2 (1270, 1604) 2 (1270,1126)
Total number of cases with PIK3CA Mutations 5 6 6
asample IDs (italics represent samples with multiple PIK3CA mutations)
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sample there was evidence of heterozygous and homozy-
gous PIK3CA mutations (Fig. 3c).
We found further evidence of genetic heterogeneity
within LCIS when analysing the SNP-array data. Although
the majority of the SCNAs reached the threshold for loss
(copy number 1) we also identified segments that did not
reach these thresholds (Fig. 4a). In order to ascertain
whether these regions could represent sub-clones we used
highly polymorphic microsatellite markers for each of the
heterogeneous regions (D15S1005 and D15S1038,
D11S897, D3S2409) and performed standard LOH ana-
lysis on DNA extracted from different areas of microdis-
sected LCIS. Microsatellite markers on 16q (D16S752) or
6q (D6S1627) were used as the control, as these regions
reached the threshold for loss.
The microsatellite analysis confirmed that where SCNAs
did not reach the threshold for loss in LCIS there was
evidence of heterogeneity, with LOH occurring in 60–80%
of the microdissected regions (Fig. 4b). Following confirm-
ation that these regions did represent sub-clones, we calcu-
lated the frequency of such segments in the different subsets
of lobular cancer using the SNP-array data as described in
“Methods”. There was a non-significant trend for the num-
ber of samples with sub-clones to increase from pure LCIS
to ILC (P = 0.08) in the classic form of the disease.
Discussion
Our study confirms the finding of previous studies that
LCIS has the same molecular changes as co-existing ILC.
We have also shown that pure LCIS and LCIS associated
with ILC (inv-LCIS) have very similar SCNAs, supporting
the hypothesis that pure LCIS is a precursor lesion. Only
five regions were significantly different between pure-
cLCIS and inv-cLCIS and these were all more common in
pure LCIS, so did not represent markers of progression.
Three of the regions were small, containing just one gene:
chr17 - RAB11FIP4; chr20 - MACROD2, overexpression
of this gene has been implicated in oestrogen-independent
growth [27]; and chrX - KLF8, oncogenic in ovarian but
not breast cancer cell lines [28]. There was also a similar
region on chr18, that was more common in both pure and
inv-cLCIS compared to ILC, containing YES1, a SRC
proto-oncogene that has recently been identified as a
possible therapeutic target in basal breast cancer [29]. It is
possible that these regions contain genes that hinder
development of the invasive phenotype. A similar finding
was made in DCIS (albeit with different genomic regions)
and the authors hypothesized that these regions could
contain genes that provide a selective advantage under
local conditions but also inhibit invasion [30].
We identified four SCNAs that increased in frequency
from pure cLCIS to inv-cLCIS and finally ILC: loss of
6q14.1-27, 8p23.2-23.1, and 22q13.31-13.33 and gain of
11q13.3. For the three regions of loss the most significant
increase in frequency came in the transition from inv-
cLCIS to cILC. Both 6q and 8p23 loss have also been found
to be more common in invasive ductal carcinoma (IDC)
than in paired DCIS [30] suggesting that there may be
tumour suppressor genes in these chromosomal regions
important in the transition of in situ to invasive carcinoma
in both DCIS and LCIS. A recent study integrating SCNAs,
promoter methylation and gene expression profiles in
luminal B breast cancers showed that 88% of the potential
tumour suppressor genes were located on 6q [31].
Deletions of 8p have been described in 50% of IDC and
37% of lobular cancers [32] and the minimal region of loss
in our study (8p23.2-23.1) includes MCPH1, a potential
tumour suppressor gene [33, 34] encoding a DNA damage
response protein which has also been implicated in breast
cancer predisposition [35]. Similarly, loss of 22q13 has been
described in IDC (not present in paired DCIS) and ILC
(but also present in paired LCIS) [36, 37].
Gain/amplification of 11q13.3 was considered the most
useful SCNA to take forward as a potential practical bio-
marker of LCIS progression as unlike the regions of loss,
the main increase in frequency occurred between the pure-
cLCIS and inv-cLCIS sub-groups. There was also evidence
of increasing amplitude of copy number gain between
the paired inv-cLCIS and ILC samples. The region
contains CCND1 and other potential oncogenes such
as FGF3, FGF4 and MYEOV and there is good evi-
dence that this region is relevant to breast cancer
[38]. Two large studies of DCIS (approximately 400
patients) have reported amplification of CCND1 in
10–12.6% of patients with pure DCIS and 14.8–17.4%
of patients with DCIS associated with invasive breast
cancer, with the majority of patients having amplifica-
tion in the paired invasive component [39, 40]. In a
much smaller series of 20 patients with florid LCIS (a
subtype putatively more likely to associated with inva-
sive disease) 25% had CCND1 amplification [41]. This,
together with the finding that CCND1 amplification is
usually homogeneous within breast carcinomas, suggests
that it is an early event in the development of some breast
cancers [42].
Other studies have identified correlation between over-
expression of cyclin D1 and amplification of 11q13 and this
over-expression has been associated with an increased risk
of recurrence in ILC [43]. One early study of ILC suggested
that cyclin D1 protein overexpression may play a role in
the transition of LCIS to ILC, as the majority of ILC
samples had over-expression but with little evidence in sur-
rounding LCIS, although the number of patients with LCIS
was not stated.
Our data support their finding that cyclin D1 over-
expression is important in the transition of LCIS to ILC, but
we have also shown that some cases of LCIS also over-
express cyclin D1 and this may be a marker of progression
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to ILC [44]. In a genome-driven classification of over 7500
breast tumours, amplification of 11q13.3 was associated
with a sub-group of ER-positive breast tumours with a
poor prognosis and chemo-resistance. This sub-group
accounted for only 3.1% of tumours in this series of mainly
IDC [45]. However, in our study 24% of cILC had 11q13.3
amplification in keeping with other series showing 11q13.3
amplification is more frequent in ILC than IDC [46]. In
our validation set, albeit very small, we found that cyclin
D1 over-expression may identify a subset of pure LCIS
that is likely to progress to ILC. As around 40% of ILC
have high expression of cyclin D1 [43], this represents a
significant subset of ILC.
Exome sequencing of this small number of LCIS and ILC
did not identify any potential biomarkers of LCIS pro-
gression. It did, however, show that activating PIK3CA
mutations are as common in LCIS as CDH1mutations. Ac-
tivating PIK3CA mutations are well-described in both ILC
and IDC, occurring in 48% of ILC (as the second most
common mutations after CDH1) and 33% of IDC [47, 48].
Fig. 4 a Sub-clonal segments on copy number analysis; b microsatellite markers confirm that sub-clonal segments on copy number analysis show
heterogeneous loss. (LOH = loss of heterozygosity)
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PIK3CA mutations have previously been reported by
Christgen et al. [49] in 1/3 patients with LCIS associated
with ILC and by Sakr et al. [48] in 7/19 patients. We con-
firmed the frequency of PIK3CA mutations in a larger set
of LCIS by Sanger sequencing, which revealed no difference
in the frequency of PIK3CA mutations in inv-cLCIS com-
pared to pure-cLCIS. The only other study to assess
PIK3CA mutations in pure LCIS was by Sakr et al. who
found no evidence of PIK3CA mutations in three patients
with pure LCIS after targeted sequencing [48]. The fre-
quency of PIK3CA mutations in ILC in our study is lower
than that reported by The Cancer Genome Atlas (TCGA)
and Sakr et al.; however, this is likely to be because both
those studies used next-generation sequencing to assess the
whole gene, whereas we targeted only the common
mutations.
So, although they are not a useful biomarker of LCIS
progression, PIK3CA mutations are an early event in lobu-
lar tumorigenesis leading to abnormal proliferation of the
breast epithelium, but importantly, they do not appear to
be the critical event leading to invasive malignancy. This
is supported by the findings of Ang et al. who identified
frequent PIK3CA mutations in non-invasive proliferative
breast lesions including DCIS, inv-LCIS and one case of
pure LCIS [50, 51].
A comprehensive analysis of 127 ILC by the TCGA has
shown that CDH1, PIK3CA, TBX3, FOXA1 and RUNX1
are the most commonly mutated genes [47]. We found no
evidence of TBX3, FOXA1 or RUNX1 mutations in the
four LCIS samples on which we performed exome se-
quencing, and identified only one TBX3 mutation in the
four ILC samples. The only other known driver gene mu-
tated in LCIS was ATRX, frequently mutated in neuro-
blastoma, low-grade glioma and glioblastoma but not
common in breast cancer. In the present series we report
splice site mutation in two additional well-known drivers
of cancer, MAP2K4 and RB1 in ILC, but not LCIS,
The TCGA data also showed that AKT signalling is
strongly activated in ILC and homozygous losses of the
PTEN locus (10q23) occurred in 6% of ILC [47]. We found
no evidence of homozygous deletions of 10q23 in LCIS in
our samples. One case of ILC did have a homozygous de-
letion at the PTEN locus, whilst this was not evident in
the paired LCIS, suggesting it is a later event in lobular
tumourigenesis. Interestingly the region encompassing
AKT3 was the locus most frequently amplified in both pure
cLCIS and inv-cLCIS and paired cILC. So, although PIK3CA
mutations do not appear to be the trigger for malignant
transformation in lobular cancer, it is possible that progres-
sion of LCIS may be related to acquisition of mutations or
alterations in other components of the PI3K/Akt pathway;
for example, expression profiling studies have shown that
PIK3R1 is significantly downregulated in the stepwise pro-
gression from normal epithelium to LCIS to ILC [52].
With the advent of next-generation sequencing intra-
tumoural heterogeneity has been found to be widespread
in invasive cancer; however, there are few data on the
intra-tumoural heterogeneity of in situ breast cancers. We
developed a relatively crude method to assess heterogen-
eity using SNP arrays and this clearly showed that sub-
clonal SCNAs increase in frequency from in situ to inva-
sive lobular carcinoma. It remains to be seen whether a
more sensitive measure of clonal diversity could be used
as a biomarker of progression to invasive disease, as it is
in Barrett’s oesophagus [53, 54]. Of interest, we have also
shown evidence of passenger mutations in LCIS not trans-
mitted to the invasive component, suggesting that, like in-
vasive disease, there is an early sub-clone expansion
process [55], with at least one acquiring critical mutations
and developing into invasive disease. Driver mutations
that are sub-clonal in the pre-invasive state then become
clonal in the invasive stage.
Conclusions
In conclusion our data have shown that pure LCIS and
LCIS co-existing with ILC have very similar SCNA profiles,
suggesting that pure LCIS is not intrinsically a different
process that is less likely to develop into invasive disease.
We have identified four SCNAs that are important in the
transformation of LCIS to ILC and provided evidence that
over-expression of cyclin D1 may identify a subgroup of
LCIS more likely to develop invasive disease. This needs
confirming in larger studies, although this will be challen-
ging, as there are few series with long-term follow up of
pure LCIS. We have also shown that PIK3CA mutations
are common in LCIS and that there is genetic heterogeneity
within LCIS, just as in ILC.
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